In vitro study showed that these engineered RBCs efficiently depleted CD19+/CD20+/CD45+ human lymphoma cells (over 90%) in mantle cell lymphoma (MCL) JeKo-1 models. Here, CD19 is linked to mantle cell lymphoma.